The “European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (version 2012)” were launched at the EuroPRevent2012 meeting in Dublin, Ireland and published simultaneously in the European Heart Journal. ¹ They were made in a new more accessible format with concise messages stressing the importance of CVD primary prevention as a key and life-long effort. […]
ESC guidelines – Intervention strategies in CVD prevention
March 12, 2013 by Leave a Comment
Table 1: Intervention strategies as a function of total cardiovascular risk and LDL cholesterol level Total CV risk (SCORE) % LDL-C levels <70mg/dL <1.8mmol/L 70 to <100 mg/dL 1.8 to <2.5mmol/L 100 to <155 mg/dL 2.5 to <4.0mmol/L 155 to <190 mg/dL 4.0 to <4.9mmol/L >190mg/dL >4.9mmol/L <1 No lipid intervention No lipid intervention Lifestyle […]
ESC guidelines – Management of hyperlipidaemia
March 12, 2013 by Leave a Comment
Table 2: Recommendations on management of hyperlipidaemia Patients at low or moderate risk Total cholesterol target <5mmol/L (< ~190mg/dL) AND LDL cholesterol target <3mmol/L (< ~115mg/dL) Patients at high CVD risk LDL cholesterol <2.5mmol/L (< ~100mg/dL) Patients at very high CVD risk LDL cholesterol <1.8 mmol/L (< ~70mg/dL) OR ≥ 50% LDL cholesterol reduction when […]
ESC guidelines – Management of diabetes
March 12, 2013 by Leave a Comment
Table 3: Recommendations on cardiovascular prevention in diabetes HbA1c HbA1c target in diabetes <7.0% (<53mmol/mol) Further reductions in HbA1c GRADE ‘weak’ HbA1c target <6.5% (<48mmol/mol) (the lowest possible safely reached HbA1c) may be useful at diagnosis. For patients with a long duration of diabetes this target may reduce risk of microvascular outcomes Statins Statins are […]
ESC guidelines – Management of hypertension
March 12, 2013 by Leave a Comment
Table 4: Recommendations on management of hypertension All hypertensive patients Lifestyle measures recommended including weight control, exercise, alcohol moderation, sodium restriction, increased fruit/vegetable consumption Use SCORE risk chart for risk stratification Consider search for subclinical organ damage, particularly in individuals at low or moderate risk (SCORE 1–4) * Systolic BP targets <140mmHg (and diastolic BP […]
Tredaptive Suspension of Marketing Authorisation
March 1, 2013 by Leave a Comment
Tredaptive, a fixed dose combination product containing extended release nicotinic acid (1000mg) and laropiprant (20mg), was authorised for use across the EU in 2008 for the treatment of dyslipidaemia in adults, particularly in patients with combined mixed dyslipidaemia and primary hypercholesterolaemia. It was used in combination with a statin, when the cholesterol lowering effect of […]
Buplex
March 1, 2013 by Leave a Comment
Company: Actavis Ireland Ltd. Legal category: OTC. Sport permitted. Active ingredient: Ibuprofen 200mg, 400mg. Description: White, oval, biconvex film coated tablets scored on one side. Can be divided into equal halves. Presentation: 200mg-12, €1.86; 24, €3.09; 50, €5.45. 400mg-12, €3.05; 24, €5.38. Indications: Mild to moderate pain such as headache (including migraine), dental pain. Primary […]
Cetriz
March 1, 2013 by Leave a Comment
Company: Actavis Ireland Ltd. Legal category: OTC. Sport permitted. Active ingredient: Cetirizine dihydrochloride 10mg. Description: White, oval, film-coated tablets marked C on one side, with J and E on either side of scored line on reverse. Can be divided into equal halves. Presentation: 30, €6.59. Indications: Relief of nasal and ocular symptoms of seasonal and […]
Cymex
March 1, 2013 by Leave a Comment
Company: Actavis Ireland Ltd. Legal category: OTC. Sport permitted. Active ingredients: Urea 1.0% w/w, cetrimide 0.5% w/w, dimeticone 350 9.0% w/w, chlorocresol 0.1% w/w. Description: White cream. Presentation: 5g, €3.75. Indications: Relief of cold sores and cracked lips. Pharmacology: The combination of urea, dimeticone, chlorocresol and cetrimide in a liquid paraffin/water base provides an emollient […]
Loading ...
